Endo Pharmaceuticals Inc. / SkyePharma plc

Post-operative pain (acute peri-surgical analgesia)

$350M Combined US/EU peak sales potential forecast for DepoMorphine (CEO guidance)

Disease Overview

Acute post-operative pain affects nearly every patient undergoing major surgery, with traditional opioid IV/PCA regimens requiring continuous infusion or repeated dosing over 24-48 hours. Inadequate post-op analgesia drives length-of-stay, opioid escalation, and patient dissatisfaction, creating demand for extended-duration single-dose formulations.

Competitive Landscape

The early-2000s post-operative pain market was dominated by short-acting parenteral opioids (morphine sulfate, hydromorphone Dilaudid, fentanyl) delivered via IV PCA pumps, plus emerging long-acting orals (OxyContin, Endo's own Percocet/Opana franchise). Endo's December 2002 deal with SkyePharma — paying $25M upfront with up to $120M total in milestones — secured rights to DepoMorphine (later branded DepoDur), a single-dose extended-release epidural morphine formulation built on SkyePharma's DepoFoam liposomal platform delivering up to 48 hours of analgesia, plus Propofol IDD-D, a preservative-free 2% propofol formulation intended to challenge AstraZeneca's Diprivan in anesthesia/sedation. DepoDur received FDA approval May 18, 2004 and launched US commercially that year, but uptake disappointed — Endo and SkyePharma terminated the Propofol IDD-D North American collaboration in April 2006 after Phase II completion, and DepoDur was eventually withdrawn from the market. The deal underscored Endo's pre-Voltaren-gel pivot to expand beyond Lidoderm/Percocet into procedural pain via partnered specialty assets.